ChemoCentryx Inc (NASDAQ:CCXI)
| 36.35 Delayed Data As of Nov 26 |  -2.53 / -6.51%Today’s Change | 9.53 Today|||52-Week Range 70.29 | -41.30% Year-to-Date |
Latest CCXI News | Press Releases
| ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos Nov 15 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 38.88 |
| Today’s open | 37.95 |
| Day’s range | 35.68 - 38.88 |
| Volume | 63,368 |
| Average volume (3 months) | 3,810,749 |
| Market cap | $2.8B |
Data as of 12:59pm ET, 11/26/2021
Growth & Valuation
| Earnings growth (last year) | +13.59% |
| Earnings growth (this year) | -100.45% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +79.61% |
| P/E ratio | NM |
| Price/Sales | 62.68 |
| Price/Book | 7.14 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CORTCorcept Therapeutics... | -0.96 | -4.27% |
| LGNDLigand Pharmaceutica... | -4.52 | -2.80% |
| ---- | ||
| PTCTPTC Therapeutics Inc | -1.28 | -3.25% |
Data as of 1:00pm ET, 11/26/2021
Financials
| Next reporting date | March 14, 2022 |
| EPS forecast (this quarter) | -$0.33 |
| Annual revenue (last year) | $64.9M |
| Annual profit (last year) | -$55.4M |
| Net profit margin | -85.31% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Carlos, California |
Forecasts
